RxDoctor Payments Data

David Morin

Internal Medicine · Kingsport, TNNPI 1750533568

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Merck at 44.2% of the total. Reporting peaked in 2021 at $3,252 and has fallen 63.8% since, to $1,178 in 2025. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,376in general payments, 2019–2025

Across 401 payments — averaging $35.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$6K
  • Novo Nordisk AS$2K
  • Eli Lilly$2K
  • Novo Nordisk$1K
  • GSK$342
  • AbbVie$336
  • plus $3K from 36 others
$1,415,745in research payments, 2019–2025

Across 400 payments — averaging $3539.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$1.1M
  • Novo Nordisk AS$221K
  • AstraZeneca$88K
  • Applied Therapeutics, Inc.$35K
  • Astrazeneca UK Limited$10K

What the payments were for

  • Consulting fees$3,18522%
  • Travel & lodging$4,84334%
  • Food & beverage$6,28444%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,376 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide33$36,154
OzempicSemaglutide21$30,996
EliquisApixaban23$26,879
Tresiba Flextouch U-200Insulin Degludec17$15,486
FarxigaDapagliflozin Propanediol18$10,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$9,810
Soliqua 100-33Insulin Glargine/Lixisenatide11$9,215
Candesartan Cilexetil19$2,320
Novolin NInsulin Nph Human Isophane12$1,951
Rosuvastatin Calcium94$1,525
Atorvastatin Calcium76$1,484
Metformin Hcl ErMetformin Hcl82$1,063
Metoprolol Succinate39$814
Pantoprazole Sodium36$455
Bisoprolol Fumarate13$452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$72$36,15433 claims
Novo NordiskOzempic$1,126$30,99621 claims
PfizerEliquis$272$26,87923 claims
AstraZenecaFarxiga$194$10,85518 claims
GSKTrelegy Ellipta$342$9,81016 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$115$9,21511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →